IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock
16 août 2022 16h15 HE
|
IN8bio, Inc
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
12 août 2022 16h15 HE
|
IN8bio, Inc
Unveiled a new preclinical program focused on developing iPSC derived gamma-delta T cells and presented early findings at the ASGCT Annual Meeting.Presented data from Phase 1 clinical trial of INB-200...
IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock
11 août 2022 22h05 HE
|
IN8bio, Inc
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients
27 juil. 2022 07h00 HE
|
IN8bio, Inc
All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and progression-free after at least one year.Patients...
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform
21 juil. 2022 07h00 HE
|
IN8bio, Inc
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cellsPatent portfolio broadly covers...
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
12 juil. 2022 08h00 HE
|
IN8bio, Inc
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio to Present at July Investor and Scientific Conferences
30 juin 2022 16h15 HE
|
IN8bio, Inc
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences
08 juin 2022 08h00 HE
|
IN8bio, Inc
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
06 juin 2022 07h00 HE
|
IN8bio, Inc
100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two patients, to date, having exceeded their expected overall survival (OS). An unmethylated GBM patient...
IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
17 mai 2022 07h00 HE
|
IN8bio, Inc
IN8bio recently unveiled expansion of its DeltEx gamma-delta T cell platform capabilities to include induced pluripotent stem cells (iPSCs).Yesterday, at the American Society for Gene & Cell...